Anti-CX3CL1 mAb therapy reduced the number of BALF M1 macrophages, but not M2 macrophages, in SKG-ILD, and only negligibly attenuated lung fibrosis in SKG-ILD. The gene discussed is CX3CL1; the disease is pulmonary fibrosis.